A prospective cohort phase III biomarker study has found that GALAD significantly increases sensitivity in HCC monitoring, but the false positive results also increase, thus indicating that GALAD's performance is mediocre and not different from that of the AFP-L3 or Hepatocellular Carcinoma Early Detection Screening (HES) scores alone [86]. Here, AFP is linked to hepatocellular carcinoma.